Bausch + Lomb Announces Second R&D “Teach-in” Webinar

Key Terms

polymerized hyaluronic acid medical

A modified form of hyaluronic acid where individual molecules are joined or cross‑linked into larger chains to make a thicker, longer‑lasting material used in medical and cosmetic injections, wound dressings, or drug delivery. Investors care because the change can extend product duration, improve performance, and create barriers to competition, affecting clinical study needs, manufacturing complexity, regulatory approval paths, and potential market value — like turning single beads into linked chains so they hold together and last longer.

silicone hydrogel medical

A silicone hydrogel is a soft, rubbery material used to make contact lenses that combines water-loving gel with breathable silicone so oxygen can reach the eye. For investors, it matters because this technology drives product comfort, safety and longer wear times, which influence sales, regulatory approval, and competitive advantage—think of it like a breathable fabric for the eye that can determine whether customers and regulators prefer one lens over another.

myopia medical

Myopia is a common vision condition where distant objects appear blurry because the eye focuses images in front of the retina instead of on it; it’s often called nearsightedness. For investors, myopia matters because rising prevalence drives demand for eye care services, corrective lenses, medical devices and treatments, similar to how increasing use of smartphones boosts related accessory markets—changes that can affect revenue, research funding and long-term product development in healthcare and consumer optics.

Event will feature detailed overviews of two innovative contact lens technologies with potential to redefine the standard of care

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D “Teach-in” webinar series that provides deeper insights on the company’s robust and differentiated product pipeline.

On Monday, June 1, 2026, at 1:00 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two promising contact lens assets currently under development:

• First-of-its-kind bioactive contact lens would be the first new contact lens material in over 25 years – designed with polymerized hyaluronic acid to provide all-day comfort, hydration and lubrication
• Cutting-edge silicone hydrogel daily contact lens featuring premium material and advanced design to help slow the progression of myopia

Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will also participate.

Registration for the live webinar hosted by Citi as part of its Head, Shoulders, Knees, and Toes series can be accessed here. Following the event, a replay will be available on the Investor Relations page of the Bausch + Lomb website.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

© 2026 Bausch + Lomb.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260506582450/en/

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

Source: Bausch + Lomb Corporation